Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
- Author:
Bo Hyun KIM
1
;
Joong Won PARK
;
Jin Sook KIM
;
Sook Kyung LEE
;
Eun Kyung HONG
Author Information
- Publication Type:Original Article
- Keywords: Biomarkers; Cancer stem cells; Carcinoma, hepatocellular; Prognosis; Sorafenib
- MeSH: Biomarkers; Carcinoma, Hepatocellular; Disease-Free Survival; Humans; Neoplastic Stem Cells; Prognosis; Real-Time Polymerase Chain Reaction; RNA; RNA, Messenger; Stem Cells
- From:Gut and Liver 2019;13(3):342-348
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Sorafenib remains the only approved molecular targeted agent for hepatocellular carcinoma (HCC); however, reliable biomarkers that predict its efficacy are still lacking. The aim of this study was to explore whether cancer stem cell (CSC) markers have a predictive role with regard to the sorafenib response in HCC patients. METHODS: We enrolled 47 patients with HCC for whom tumor samples obtained before starting sorafenib treatment were available. RNA was extracted from formalin-fixed, paraffin-embedded samples, and real-time polymerase chain reaction was used to quantify mRNA expression of the CSC genes EpCAM, CD13, CK8, CD24, CD44, CD90, CD133, SALL4, ALDH1A1, ALB, and AFP. RESULTS: Of 47 patients, 14.9% and 74.5% had vascular invasion and extrahepatic spread, respectively. Patients with low CD133 expression tended to have longer progression-free survival (PFS) than those with high CD133 expression (5.5 months vs 4.0 months), although without statistical significance. The expression levels of other markers were not associated with PFS. When examining markers in combination, patients with high CD133 and CD90 expression had shorter PFS rates than those with low expression (2.7 months vs 5.5 months; p=0.04). Patients with low CD133 and EpCAM expression demonstrated better PFS than those with high expression (7.0 months vs 4.2 months; p=0.04). Multivariable analysis indicated that an Eastern Cooperative Oncology Group performance status score of 1 and high CD133/CD90 expression were significantly associated with shorter PFS. CONCLUSIONS: Overexpression of the CSC markers CD133 and CD90 in HCC was associated with poorer response to sorafenib. These two genes may serve as predictive biomarkers for sorafenib therapy.
